Articles from Evinova

Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc. (“Astellas”), AstraZeneca and Bristol Myers Squibb to accelerate their global clinical development using Evinova’s AI-native platform. Each partner company has opted in to share operational data with Evinova, enabling the platform to provide benchmarks and smarter recommendations intended to further accelerate clinical trials and improve patient outcomes.

Evinova today announced that Bristol Myers Squibb has signed an agreement to optimize clinical trials with Evinova’s AI-native clinical development platform. Under the terms of the agreement, Bristol Myers Squibb will deploy the Cost Optimizer module of Evinova’s Study Designer across the company’s global portfolio, harnessing advanced artificial intelligence to improve insight-driven decision making, identify productivity opportunities, and unlock more efficient trial designs that accelerate innovation and improve experience for sites and patients.

Yesterday, during the 8th China International Import Expo (“CIIE”), Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, and Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, announced a strategic collaboration in artificial intelligence (AI).

A new study conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD) and supported by Evinova, a global clinical trial technology company with proven published outcomes for sponsors, sites and patients, reveals that investigative sites are increasingly adopting and self-investing in digital tools to support the conduct of clinical research.

Evinova, a global clinical trial technology company with proven published outcomes for sponsors, sites and patients, announced today an agreement with Quantum Leap Healthcare Collaborative™ (QLHC) to incorporate Evinova’s remote patient monitoring (RPM) solution into I-SPY 2.2. I-SPY 2.2 is the largest and longest-running 'platform' trial that provides a framework to study multiple novel therapeutic treatment arms for women with newly diagnosed, locally advanced breast cancer. Evinova’s RPM module will be used to alert healthcare professionals of early symptoms of interstitial lung disease (ILD), a potential adverse event for one treatment arm in the study.